Literature DB >> 6668545

Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs.

S Tanaka, Y Kasuya, Y Masuda, K Shigenobu.   

Abstract

Platelet activating factor (PAF) showed profound and long-lasting hypotensive effects in normotensive and spontaneously hypertensive rats, guinea pigs, rabbits and dogs. Sensitivity to PAF was different among the animal species. The magnitude and duration of the hypotensive effect was dose-dependent. Pharmacological studies suggested that the hypotensive action was unlikely to be caused by the actions on the central or autonomic nervous systems but seemed to be mainly due to some direct action(s) on the peripheral blood vessels.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6668545     DOI: 10.1248/bpb1978.6.866

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  7 in total

1.  Involvement of nitric oxide pathway in the PAF-induced relaxation of rat thoracic aorta.

Authors:  H Moritoki; T Hisayama; S Takeuchi; H Miyano; W Kondoh
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

2.  Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.

Authors:  Y Yang; E M Nemoto; S A K Harvey; V M Subbotin; C R Gandhi
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis.

Authors:  Yong-Ping Yang; Xue-Mei Ma; Chun-Ping Wang; Jun Han; Yin-Ying Lu; Yi Xiang; Shu-Hui Su; Yong-Yi Feng
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

4.  Endothelium-dependent vasodilator effects of platelet activating factor on rat resistance vessels.

Authors:  K Kamata; T Mori; K Shigenobu; Y Kasuya
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

5.  Possible involvement of endothelium-derived hyperpolarizing factor (EDHF) in the depressor responses to platelet activating factor (PAF) in rats.

Authors:  Y Tanaka; S Hayakawa; T Imai; A Akutsu; H Hirano; H Tanaka; T Nakahara; K Ishii; K Shigenobu
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

6.  TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock.

Authors:  P Canale; F Squadrito; D Altavilla; M Ioculano; B Zingarelli; G M Campo; G Urna; A Sardella; G Squadrito; A P Caputi
Journal:  Agents Actions       Date:  1994-10

7.  Action of the racemate and the isomers of the platelet-activating factor antagonist bepafant (WEB 2170) after oral administration to guinea-pigs and rats.

Authors:  H O Heuer; B Keller; K Urich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.